Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
3 Dependable Stocks With Dividend Yields Above 5%
10:53am, Wednesday, 24'th Aug 2022
These three will pay you well while you wait for their shares to rebound.
Haleon: World's Largest Over-The-Counter Business Looks Like A Buy Here
07:11pm, Monday, 22'nd Aug 2022 Investing.com
Gilead (GILD) Twice-Yearly HIV Treatment Gets EC Approval
03:57pm, Monday, 22'nd Aug 2022 Zacks Investment Research
Gilead (GILD) HIV treatment Sunlenca gets approved by the European Commission for adults with multi-drug resistant HIV infection for whom it is otherwise not possible to construct a suppressive anti-v
Is Hartford Multifactor Developed Markets exUS ETF (RODM) a Strong ETF Right Now?
10:20am, Monday, 22'nd Aug 2022 Zacks Investment Research
Smart Beta ETF report for RODM
Clouds Are Gathering (Again) For GSK
01:26am, Monday, 22'nd Aug 2022
GSK was having a turnaround year, with drugs pipeline strong and H1 results impressive. Zantac lawsuits are presenting a significant risk to investing in GSK.
The Rise and Fall of Novavax
12:45pm, Sunday, 21'st Aug 2022 The Motley Fool
The story of Novavax stock over the last few years would make an amazing book.
Pharma Stock Roundup: End of SNY's Amcenestrant Development, FDA Updates for AZN, GSK
01:07pm, Friday, 19'th Aug 2022 Zacks Investment Research
Sanofi (SNY) ends the development of breast cancer candidate, amcenestrant. Novartis' (NVS) lung cancer candidate, canakinumab fails a phase III study. FDA grants priority review to AstraZeneca (AZN)
GSK NDA for Myelofibrosis Candidate Gets FDA Acceptance
12:46pm, Thursday, 18'th Aug 2022 Zacks Investment Research
GSK's NDA for momelotinib for treating myelofibrosis was based on data from key phase III studies, including the pivotal MOMENTUM study.
GSK NDA for Myelofibrosis Candidate Gets FDA Acceptance
09:47am, Thursday, 18'th Aug 2022
GSK's NDA for momelotinib for treating myelofibrosis was based on data from key phase III studies, including the pivotal MOMENTUM study.
Plaintiff in first Zantac lawsuit set for trial drops case
02:54pm, Wednesday, 17'th Aug 2022
The plaintiff in the first lawsuit over the heartburn drug Zantac scheduled to go to trial has agreed to drop his case, according to his attorney and drugmakers named as defendants.
Recent Stock Purchase August 2022
02:40pm, Wednesday, 17'th Aug 2022
This month I deployed more cash than last month totaling almost $2,000. People like to talk about crypto volatility but the market in recent months has plenty of examples of wild price swings too.
Zantac lawsuit drop ‘not as significant as it appears' for GSK stock, analysts say
07:09am, Wednesday, 17'th Aug 2022
The withdrawal of the plaintiff in the first lawsuit over GSK's heartburn drug Zantac may not be “as significant as it first appears” for the company's shares, say analysts from RBC Capital Market
GSK: First Zantac case plaintiff drops lawsuit
03:19am, Wednesday, 17'th Aug 2022
The first of the legal cases against companies that sold the heartburn drug Zantac ended before it started after the plaintiff dropped his case. Joseph Bayer, who brought the action against GSK PLC (L
Gilead (GILD) Announces Positive Data on Breast Cancer Drug
05:10pm, Tuesday, 16'th Aug 2022 Zacks Investment Research
Gilead (GILD) breast cancer drug Trodelvy improves overall survival in pre-treated HR+/HER2- metastatic breast cancer patients. The company will also acquire the remaining rights to the drug.
Plaintiff drops suit in first Zantac trial
04:45pm, Tuesday, 16'th Aug 2022
Yahoo Finance health care correspondent Anjalee Khemlani details how the first case against pharmaceutical company GSK over its Zantac derivative was voluntarily dismissed.
